HealthRX vs Cora Health
Two GLP-1 desks, one scoreboard. We put HealthRX and Cora Health head-to-head on the published Brief Score — the same six factors, scored the same way.
HealthRX
The verdict
HealthRX takes this head-to-head.
HealthRX scores 86 to 77 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.
That doesn't make Cora Health a bad call — it's best for readers who want flat-rate compounded glp-1 from $99/mo with named pharmacy disclosure. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| HealthRX | Cora Health | |
|---|---|---|
| Brief Score | 86/100 (B) | 77/100 (C) |
| Semaglutide | $189/mo | From $99/mo (all doses, 12-month plan, compounded) |
| Tirzepatide | $349/mo | From $135/mo (all doses, 12-month plan, compounded) |
| Coverage | Not publicly listed | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.
Cora Health: New to the tracker on 1 August 2026. The published line reads From $99/mo (all doses, 12-month plan, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.